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Sunllnal'y 
Staphylococcal enterotoxin B (SEB) is both a superantigen  and toxin.  As a superantigen,  SEB 
can bind to major histocompatibility complex (MHC) class II molecules to form a ligand for 
ot/B T  cell receptors bearing particular VB elements. As a toxin, SEB causes rapid weight loss 
in mice sometimes leading to death.  We show here that  both of these functions map  to the 
NH2-terminal portion of the toxin. Three regions were identified: one important  in MHC class 
II binding, one in T cell recognition, and one in both functions. These results support the conclusion 
that the toxicity of SEB is related to massive T cell stimulation and release of cytokine mediators 
and  show that  the residues interacting  with  MHC and the T  cell receptor  are  intertwined: 
S 
taphylococcus aureus produces a set of exotoxins harmful 
to humans and other species (1-4). These include a group 
of  enterotoxins  (Staphylococcal  enterotoxins  [SEs]I),  as- 
sociated with food poisoning;  toxic shock syndrome toxin 
1 (TSST-1),  associated with toxic shock syndrome; and ex- 
foliating toxins (ExF), associated with scalded skin syndrome. 
Many of these toxins were purified to homogeneity some years 
ago and most have been cloned and sequenced (5-12). Never- 
theless,  there still is no consensus on their  mechanisms  of 
action in  human  diseases. 
These toxins were shown some time ago to be powerful 
T cell stimulators (13-15), a capacity that we and others have 
recently attributed to their properties as microbial superan- 
tigens (16-24). As superantigens,  each toxin has the ability 
to bind to class II molecules of the MHC and create a ligand 
for virtually all T cell ot/~ antigen receptors containing par- 
ticular variable dements on the B chain (VB). Amino acid 
differences in the other receptor variable components (D~, 
JB, Vot, Jot) do not play a major role in this interaction. Since 
there are a limited number  of V~s (at least 57 in humans 
[25] and 22 in mice), the frequency ofT cells reactive to each 
toxin is very high.  A  recent  study (26) has indicated  that 
T cell stimulation occurs by interaction of the MHC-bound 
toxin with specific residues in the V/3 element lying on the 
side of the receptor rather than the variable face thought  to 
contact conventional antigen bound to MHC. We have sug- 
1  Abbreviations used in this paper: SE, Staphylococcal  enterotoxin; TSST-1, 
toxic shock syndrome toxin 1. 
gested that the pathology of these toxins involves the mas- 
sive release  of bioactive cytokines accompanying this high 
frequency T  cell response in vivo (22,  27). 
Although binding of the toxin to class II MHC is a pre- 
requisite for T  cell recognition  (16,  28-30),  the process is 
much more permissive than  that  seen with the binding of 
conventional peptide antigens. Whereas peptide antigens are 
very dependent on allelic MHC residues for binding,  toxin 
superantigens bind to a wide variety of allelic  and isotypic 
forms of class II MHC in mouse and humans (31-34). Fur- 
thermore,  T  cells  rarely recognize peptide antigens bound 
to allo-MHC molecules, while individual T  cell clones can 
respond  to toxins bound not only to various allelic  forms 
of MHC, but also to different class II isotypes and even to 
xenogenic class II.  These observations have suggested that 
toxin superantigens bind to MHC at a relatively conserved 
site outside the allelically  hypervariable groove thought  to 
bind conventional peptide antigens. 
Our purpose in the present study was to perform a muta- 
tional analysis of one of the toxin superantigens,  SEB, to define 
regions of the toxin involved in MHC binding and TCR V3 
interaction,  and to relate the functions of these regions to 
the in vivo toxic effects of SEB. 
Materials  and Methods 
Polymerase Chain Reaction (PCR).  PCRs (35) were performed 
using AmpliTaq recombinant Taq polymerase and the DNA Thermal 
Cycler from Perkin Elmer Cetus (Norwalk, CT). 20-30 cycles  were 
performed with 1-min denaturing  and annealing steps, and an ex- 
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>500 bp. Template concentrations were 1-10 nM and oligonucleo- 
tide primer concentrations were 1 #M. The concentration of the 
dNTPs was 200 #M, except when attempting to introduce muta- 
tions, where the concentration of one of the dNTPs was reduced 
to 20 #M. 
SEB Construct.  The SEB gene was overexpressed in Escherichia 
coli as follows.  A linearized plasmid containing the genomic SEB 
gene (36) was used as a template in a PCR utilizing oligonucleo- 
tide primers that flanked the portion of the gene encoding the ma- 
ture SEB without the signal peptide. The 5' primer was 5'-TAG- 
GGAATTCCATGGAGAGTCAACCAGA-Y, which contained an 
EcolLI site placing the SEB gene in-frame with the LacZ gene when 
cloned into pTZ18K (Pharmacia Fine Chemicals, Piscataway,  NJ). 
This oligo also had an NcoI site that added an ATG between the 
lacZ gene fragment and the beginning of the SEB gene so that 
the SEB gene could be moved easily to other plasmids carrying 
its own initiation ATG. The 3' primer, which contained a HindlII 
site after the termination codon of the SEB gene, was 5'-AGC- 
TAAGCTTCACTTTTTCTTTGTCG-Y. The PCK fragment was 
digested  with  EcoRI  and  HindlII  and  ligated  into  EcoKI/ 
HindlII- digested pTZ18K. E. coli XL1-Blue (Stratagene, La Jolla, 
CA)  was  transformed with  the plasmid,  a  single  transformant 
picked, and the insert in its plasmid (pSEB2)  sequenced to check 
that it had no mutations.  Upon induction  this construct led to 
overproduction of mostly cytoplasmic SEB ("~10 #g/ml of broth). 
However, rather than producing a LacZ/SEB fusion protein,  the 
bacteria produced a protein with the same apparent molecular weight 
as secreted SEB from S. aureus (Fig.  1 a). Either the LacZ portion 
of the fusion protein was cleaved in vivo from the majority of the 
SEB or the ATG introduced between LacZ and SEB was for some 
reason a more efficient translation initiation site than that of LacZ. 
In the course of these studies,  this construct was modified to in- 
troduce silent base changes which produced useful restriction sites 
in the 5'-end of the gene. 
Generation of  SEB Mutants.  SEB mutants were prepared in two 
ways. First,  to introduce random mutations along the entire length 
of the SEB gene, the SEB construct was prepared again, but the 
PCR was performed with the concentration of either dATP or dTTP 
reduced 10-fold in order to increase the error rate of Taq polymerase 
(37). This reduced the amount of product by •5-10  fold. The prod- 
ucts of the two reactions were combined and cloned into pTZ18K 
as above and individual transformants screened for mutant SEB as 
described below (BR mutants). Of ,~400 toxin-producing trans- 
formants screened, 10 were identified as functional mutants by their 
reduced ability to stimulate T cells. Low concentrations of dCTP 
and dGTP were tried as well, but less reduction in product resulted 
and no mutants were detected in screening ,~200 transformants. 
A second PCK method was used to introduce random mutations 
in ,~60-75 base-defined regions of the SEB gene. The following 
oligonucteotides (A, B, and C), positioned as shown in Fig. 2, were 
synthesized with each position containing 1% each of the three 
incorrect bases:  A-,  5'ATTCCCTAACTTAGTGTCCTTAATAG- 
AATATATTAAGTCAAAGTATAGAAATTG~AGAY; B-, 5' 
AGCTAGATCTTTGTTTTTAAATTCGACTC  GAACATTATC  - 
ATAATTCCCGAGCTTAY; C +, 5'CCGGATCCTAAACCAGAT- 
GAGCTCCACAAATCTTC  CAATTCACAGGCCTGATGGAA- 
AATATGAAAGTTTGTATY. These mutant oligonucleotides were 
used as primers in a PCK reaction with either a vector (A and B) 
or internal SEB (C) oligonucleotide as the other primer and SEB 
as a template. Therefore, each molecule of the synthesized SEB frag- 
ments was predicted to have two to three random base mutations 
in the region corresponding to the mutant primer. The mutant 
fragment was incorporated into the SEB gene, either by using it 
plus anqther fragment containing the 3' portion of the gene as 
mixed template in a PCK reaction to resynthesize a fuU-length SEB2 
gene as previously described (38, 39), or by digestion with the ap- 
propriate restriction enzymes and ligation into pSEB2 from which 
the corresponding region had been removed. 
DNA Sequencing.  Plasmid inserts were sequenced directly by 
the dideoxynucleotide method (40) using Sequenase (U.S. Biochem- 
ical Corp., Cleveland, OH) with a modification for double-stranded 
supercoiled plasmid templates (41). Several oligonucleotide primers 
were used matching sequences  either in the vector or SEB insert. 
Anti-SEB mAbs.  10 mAbs specific for at least five epitopes of 
SEB were produced by standard methods from B10.Q(BBR) im- 
munized multiple times with SEB. The properties of these anti- 
bodies will be described in detail elsewhere (Kappler, J.  W., and 
P. Marrack, manuscript in preparation). One of these antibodies, 
B344.1,  was  used  both  for  quantitation  and  immunoaffinity 
purification of SEB and its mutants in these experiments. B344.1 
is an IgG1 that was chosen because initial characterization showed 
that it had a high affinity for SEK bound equally well to all of 
the SEB functional mutants, could detect and immunoprecipitate 
SEB bound to MHC class II molecules, and did not block T  cell 
recognition of SEB bound to DR (data not shown). 
ELISA for SER  The amount of SEB in preparations was de- 
termined in an ELISA. Microtiter wells were coated overnight with 
a solution of 6 #g/ml natural SEB (Sigma Chemical Co., St. Louis, 
MO). The wells were then incubated with 25% FCS and washed 
thoroughly. Various concentrations of known and unknown SEB 
preparations were added to the wells as inhibitor followed by a con- 
stant  amount  of anti-SEB antibody (polyclonal rabbit  anti-SEB 
[Toxin Technology, Madison, WI] in BR experiments and mono- 
clonal anti-SEK B344, in BA, BB, and BC experiments). After I h, 
the wells were washed thoroughly, and the bound antibody was 
detected by standard techniques using alkaline  phosphatase cou- 
pled either to goat anti-rabbit IgG (Sigma Chemical Co.) or to 
goat anti-mouse IgG1 (Fisher Scientific Co., Pittsburgh, PA) and 
p-nitrophenyl phosphate as substrate. The OD of the reaction at 
405 nm was related to the dose of inhibitor and the concentration of 
the SEB in the unknown estimated by computer analysis of the data. 
Preparation of Recombinant SER  For initial screening, individual 
colonies of transformants picked from agar plates were transferred 
to wells  of 96-well microtiter plates containing 100/~1 of 2XYT 
and carbenicillin.  A replicate plate was prepared except that the 
media contain 1 mM IPTG as well. Both were incubated overnight 
at 37~  with shaking.  50 #1 of glycerol was added to each well 
of the first plate, which was mixed and then stored at  -70~ 
To prepare SEB-containing lysates,  each well of the second plate 
received  50 #1 of HNM buffer (10 mM Hepes, pH 7.0, 30 mM 
NaC1,  5  mM  MgCI2)  containing  3  mg/ml  lysozyme and  300 
#g/ml DNAse I. The plate was incubated at 37~  for 15 min, 
frozen, thawed three times, and centrifuged to pellet debris.  The 
supernatants were transferred to a new plate and tested for the pres- 
ence of SEB both by ELISA and T  cell hybridoma stimulation. 
This method produced preparations containing between 0.3 and 
10 #g/ml of SEB. 
To produce purified mutant SEB, transformants were recovered 
from the 96-well plate stored at  -70~  Bacteria from overnight 
cultures (1 vol) containing IPTG were collected by centrifugation, 
resuspended in a 1:10 vol of HNM buffer containing 1-2 mg/ml 
lysozyme and 10 #g/ml DNAse I, and frozen and thawed three 
times. The suspension was centrifuged at 15,000 g for 20 min to 
remove bacterial debris,  and  the supematant was harvested and 
faltered (0.2 #). The filtrate was passed through a column containing 
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a mAb to SEB (/3344). The beads were washed thoroughly with 
PBS and the toxin was eluted with 0.1 M glycine.HCL (pH 2.7) 
and neutralized with 1 M NazCO3. The SEB was concentrated to 
1 mg/ml and its buffer changed to BSS using Centriconl0 micro- 
concentrators (Amicon Corp., Derivers,  MA). This method yielded 
3-10 mg of toxin per liter of  bacterial culture. SEB and its mutants 
produced in this manner were ;>95% pure as  judged by SDS-PAGE, 
although  some proteolytic cleavage was evident (Fig. 1 a). 
Computer Analysis of Primary Sequence,  Computer analysis of 
the primary sequence  of  SEB predicting the hydrophilicity (42) and 
secondary structure (43, 44) of particular regions was performed 
using MacVector Version 3.5 (International Biotechnology, Inc., 
New Haven CT). 
Results 
Initial Production  of  SEB Mutants.  SEB mutants were pre- 
pared in two ways,  as described in Materials and Methods. 
Random mutations were introduced by PCR into the entire 
319-amino acid toxin (BR series)  or into "~20-amino acid 
defined regions (1-3) using randomly mutagenized oligonu- 
cleotide primers (BC, BA, BB series). For primary screening, 
total lysates were prepared from individual transformants con- 
taining a potentially mutant SEB gene. Aliquots of each ly- 
sate were tested for the presence of functional toxin by stim- 
ulation of murine T cell hybridomas bearing cx/fl receptors 
with either Vfl7 or VflS.3, using human DR-expressing cell 
lines as presenting cells. Lysates deficient in stimulating ei- 
ther of these hybridomas were assayed for the presence of 
SEB protein to rule out mutations affecting the level or the 
full length of t-he SEB produced. Plasmids from those pro- 
ducing protein were sequenced to locate the mutation. The 
sequences of the mutants are shown in Fig.  2. 
The Taq polymerase error-induced random mutants (BR) 
were clustered in  three regions  (1,  2,  4),  all  in  the NH2- 
terminal 93 amino acids of the molecule (except an additional 
conservative mutation in one case, BRo374,  in the COOH- 
terminal half of the molecule). As predicted by their method 
of generation, all but one of these mutations involved a nucleo- 
tide substitution of A  to G or T  to C, and only one silent 
mutation was found elsewhere in their sequences (data not 
shown). Additional mutants were generated in region 1 or 
2 with mutant oligonucleotide C  or A  (BC, BA mutants). 
Region 3 was originally discovered as a single mutant (BA- 
62) involving the last amino acid covered by oligonucleotide 
A. The mutant had a different phenotype than the other BA 
mutants (see below). Additional mutants were produced in 
this region with mutant oligonucleotide B  (BB  mutants). 
Mutations in region 4 were eliminated from further analysis, 
because we felt that interfering with the conserved disulfide 
forming cysteine at position 93 could have far reaching un- 
predictable effects. In addition, several mutants were not fur- 
ther characterized either because they involved more than one 
region (BR-474, BA-72), produced highly degraded toxin (BR- 
267), or were identical to an already existing mutant (BA-50). 
Binding of Mutant SEB to HLA-DR.  Since binding  to 
MHC class II is a prerequisite for toxin recognition by T 
cells, the mutations could have affected either the ability of 
Figure 1.  (a) Recombinant and natural SEB have the same molecular 
mass 2/~g of recombinant SEB purified from E. coli and SEB purified from 
S. aureus cultures (Sigma Chemical Co.) were analyzed by SDS-PAGE using 
a 12% gel under reducing conditions. Molecular mass markers (in kD): 
B-phosphorylase, 94; bovine albumin, 69; ovalbumin, 45; carboxyhse, 30; 
soybean trypsin inhibitor, 21; lysozyme,  14. (b) Binding of SEB to DR 
on LG2 cells. 12SI-labeled  LG2 cells (53) were incubated with or without 
50 #g/ml recombinant SEB for 2 h at 37~  A cell free lysate was prepared 
in 1% digitonin and incubated for 4 h at room temperature with Sepharose 
beads coupled with 3 rag/m1 B344 anti-SEB mAb. The beads were washed 
thoroughly, and the labeled bound material was analyzed by SDS-PAGE 
under reducing conditions (54) and autoradiography.  As a control, beads 
bearing the anti-DR mAb, L243 (55), were used (1/20 the volume of ly- 
sate used with the anti-SEB beads). Molecular mass markers (in kD): bo- 
vine albumin, 69; ovalbumin, 45; chymotrypsinogen, 27; soybean trypsin 
inhibitor, 21; myoglobin, 17; lysozyme 14. 
the toxin to bind to DR molecules or the recognition of this 
complex by the TCR-cx/~ To help distinguish these two pos- 
sibilities, we used the HLA-DR1 homozygous lymphoblastoid 
line, LG2 (45).  SEB binds to DR molecules on LG2 (Fig. 
1 b). We prepared immunoafl~nity-purified  toxins and assessed 
their ability to bind to LG2 using flow cytometry with the 
same anti-SEB mAb used to purify the SEB and its mutants. 
The results are shown in Fig.  3. 
The binding by four of the region 1 mutants to LG2 was 
indistinguishable from that  of unmutated SEB. The other 
three mutants  were reduced in  their binding  capacity by 
'~100-fold.  These results suggest that residues between 14 
and 23 within region 1 are important in MHC binding. Five 
of the seven mutations involved residue 23N.  In only one 
case  (BR-291,  23N-~S)  did  this  mutation  reduce MHC 
binding.  These results suggest residue 23N may be impor- 
tant in both in MHC binding and V~/interaction.  Region 
2 mutants all bound poorly to LG2,  "~1,000  times poorer 
than SEB, indicating that region 2 defines a stretch of amino 
acids,  especially 44F,  important in binding of the toxin to 
class II MHC. Region 3 mutants were essentially unaffected 
389  Kappler et al. ]  10  20  30  40  50  60  70  80  90  SS ,.Ira,,,-  1  190 
I  I  I  I  I  I  I  I  I  ["  (~0  I 
SEB  ES  QPDPKp~S  S  ~TG~LYI3DNHVS  A  I  NVKS  !I~F  LyFDL  I  YS  I  KIXI'~VEFKNKD  LADKYKD~  ~~  S  /  /  QELD//I  KF  I 
BR-75  .......  ................  .....  .............................  ........... 
BR.257!!!!!)!~I~!!!!!!!!!!!!!!  !BR-210  .......  ................  iii}iiiiiiiii!!!!!lli  .....  .............................  !!!!!!!!!!!!!!!!!!!!!!!!!!!  ii  ...........  !!  !!!  BR-291 .......  ~iiiiii~:!i  i~:ii~iS  ................  .....  .............................  i..  ~..i  ~. 
BC-6  ...... 
BR-358  ....... 
BR-374  ....... 
BA-3 
BA-15 
BA-24 
BA-31 
BA-50 
BA-53 
BA-62 
BB-14 
BB-21 
BB-47 
BR-30 
BR-311 
BR-474 
BA-72 
BR-267 
!iiiii  i i~ii!ii  ...............  i~  i is  ::::  l'  ii i' .............................  ................................................  ,, 
.............................  :~!:'~:i:~':i  ........... 
::.x:::, 
::::::::i 
............................. ii~'ii~:~i~,~ii  .........  I- 
..............................  ............ 
...........................  i:~:~:~:~ ........... 
.............................  ii~iiiii~!  ........... 
I  C  ~  ~  A 
Figure 2.  Sequences of the SEB mutants used in this study. Partial amino acid 
generated in this study are shown with a dash, indicating identity to unmutated 
shown as well. See Materials and Methods for details. 
I 
B  I 
sequence of SEB (8) is shown. The sequence of the SEB mutants 
SEB. Positions of oligo nucleotides used to generate mutants are 
in binding to LG2, strongly suggesting that this two-amino 
acid region (60N,  61Y) is important in V/~ interaction. 
Effect of Mutations on  T  Cells Bearing Different V[3 Ele- 
ments.  The SEB mutants were originally identified because 
they stimulated either  a  VB7 +  or  a  VB8.3 +  T  cell  hy- 
bridoma poorly. To assess the effect of the SEB mutations 
on T cell recognition in more detail, we retested the purified 
mutant toxins at various doses on additional T cell hybrid- 
,ooo  T  1  Region 1  Region 2  Region 3 
100  + SEB  + SEB 
￿9 BR-257 
A BC-66  I/'P  I1(/)  g  + SEB 
xBC'S8  //~  fd  OBR_75  BR-358 
￿9 _,~  ,~f  i  BR-3741"  ~"  "  10  jlfhr  a~//'-  OBR-291  J-  ~  ~  ABA-3  1  ~  ABB:4; 
",~  r  ~  II BR-210  l/  ~  ~ BA'15 i  -~  [] BA-31BA'24  OO BA-62BA-62 
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Figure 3.  Binding of SEB and its mutants to DKl-bearing LG2 cells. 3  x  104 LG2 cells were incubated in I00 gl of tissue culture medium over- 
night at 37~  with various concentrations of SEB or its mutants. The cells were washed thoroughly and incubated for 30 min at 4~  with ~1 gg/ml 
of the anti-SEB mAb, B344.1. The cells were washed again and incubated for 15 min at 4~  with fluoresceinated goat anti-mouse IgG1 (Fisher Scientific 
Co.). The cells were washed again and analyzed for surface fluorescence with a Epics C flowcytometer. The results are plotted as the mean relative 
fluorescence of the cells corrected for the fluorescence seen with the secondary reagent alone vs. the amount of toxin added. (Region I) (+) SEB, (0) 
BR-75, (11) BR-210, (A) BR.-257, (O) BR-291, (I-q) BC-6, (A) BC-66, (x) BC-88. (Region 2) (+) SEB, (0) BR-358, (ll) BR-374, (A) BA-3, (O) 
BA-15, (l-q) BA-24, (A) BA-31, (x) BA-53. Region 3: (+) SEB, (0) BB-14, (11) BB-21, (A) BB-47, (O) BA-62. 
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to recognize SEB (V~7, V~8.1-3) (16,  20, 24). The results 
are shown in Figs.  4-6. 
Among the region I mutants  (Fig.  4), the five involving 
23N (BR-257, BR-291, BC-6, BC-66, BC-88) stimulated all 
of the hybridomas poorly, despite the fact that four of these 
bound to DR as well as unmutated SEB did.  These results 
indicate that residue 23N is an important amino acid for VB 
interaction, but because the fifth mutant involving this amino 
acid, BR-291, bound poorly to MHC, this amino acid may 
influence MHC binding as well. The other two region I mu- 
tants also stimulated poorly. In the case of BR-75, this may 
have been due primarily to its poor binding to DR, but the 
effect of the BR-210 mutation was several orders of magni- 
tude greater on T  cell stimulation than on binding to DR, 
Taken together, these results suggest again that during T cell 
recognition of SEB bound to DR, the amino acids in region 
1 are situated in the trimolecular  complex at  the junction 
between VB and MHC, so that individual residues may in- 
teract  with  either component. 
The mutations in the other regions produced less compli- 
cated phenotypes. All of the region 2 mutants were defective 
in stimulation of all of the T  cell hybridomas, regardless of 
the V~/element in their receptors (Fig.  5). There were small 
differences,  but in general the effect of mutations on stimula- 
tion was about the same as that seen on DR binding. These 
results were consistent with the conclusion that  mutations 
in region  2 primarily  affect DR binding. 
The two-amino acid region 3 mutants were the most dis- 
criminating  (Fig. 6). Despite the fact that random mutants 
in a 20-amino acid stretch flanking this region were gener- 
ated,  all mutations  affecting function were found in these 
two amino acids.  These mutants failed to stimulate the hy- 
bridomas bearing V37 and V38.1, but stimulated the V38.2 
hybridoma very well and the V38.3 hybridoma about as well 
as unmutated SEB. Since all these mutant toxins bound DR 
as strongly as unmutated SEB, this region appears to be es- 
sential for toxin interaction with V37 and V38.1, but not 
V38.2 or V38.3. To insure that this property was not pecu- 
liar to these particular hybridomas, we tested the toxins with 
four other T  cell hybridomas: one V37 + , two V38.1 +, and 
one V~8.3 +. The results were indistinguishable from those 
in Fig.  6  (data not  shown). 
Requirement for  T  Cell  Interaction for In  Vivo  Effects of 
SEB  The question of how important the superantigen prop- 
erties of the bacterial toxins are to their in vivo toxic effects 
is unresolved. Our previous experiments suggested that the 
toxicity of SEB in mice was related to its ability to stimulate 
T cells in a V~/-specific manner,  since the toxic effect of SEB 
was directly related to the frequency of T  cells bearing the 
relevant VB elements (27). However, the ability of some of 
the S. aureus toxins to bind to class II on monocytes and stimu- 
late the production of cytokines such as TNF and II.,1 (46) 
opens the possibility that direct monocyte stimulation may 
be sufficient to account for much of the toxin pathology in 
some situations. 
To test this idea, we injected mice with various concentra- 
tions of region I mutant BR-257, which binds very well to 
class  II but does not stimulate T  cells  except at extremely 
high levels. For controls we used unmutated SEB and mu- 
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Figure 4.  Stimulation of T  cells 
hybridomas by region  1 SEB mu- 
tants. Preparations of purified SEB 
or the region 1 mutants were tested 
for their ability to stimulate a col- 
lection of T cell hybridomas bearing 
each of the VB elements known to 
recognize SEB: KS-20.15(VB7), KS- 
6.1(V~8.2),  KS-47.1(V~8.3)(16), 
and  K16-57(V~8.1)  (56).  Various 
concentrations of the toxins were in- 
cubated at 37~  overnight with 3 
￿  104 DR1 + LG2 cells in 200/~1 
of tissue culture medium.  5  x  104 
T  cell hybridomas cells were added 
in 50/~1, and the mixture was in- 
cubated  overnight  again.  The  re- 
sponse of the T cell hybridomas was 
measured  as  the  amount  of  1I.-2 
secreted as previously described (57, 
58).  Symbols are as in Fig.  3. 
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might contaminate the preparations, we used C3H/HeJ mice, 
a strain defective in LPS responsiveness. Since rapid weight 
loss is one of the most obvious immediate  toxic effects of 
SEB in mice (27), we weighed the mice daily after the injec- 
tion. The results are shown in Fig. 7. Mice given either 50 
or 100/~g of recombinant SEB lost weight rapidly over 3-4 d, 
and all of the mice were dead by day five. Mice given mutant 
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Figure 6.  Stimulation of T  cells 
hybridomas by region 3  SEB mu- 
tants. Preparations of SEB and re- 
gion 3 mutants were tested for their 
ability to stimulate murine T  call 
hybridomas as in Fig.  5.  Symbols 
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mice were weighed and then given 
balanced salt solution (BSS) con- 
taining nothing (O) or 50 #g (left) 
or 100 #g (right) of recombinant 
SEB (I) or the mutant SEBs BR- 
257 (A) or BR-358 (O). The mice 
were weighed daily at the same time 
of day until they died. Results are 
presented  as  the  average percent 
change from the starting weight for 
the surviving mice. One mouse in 
the 100/~g  of SEB group died by 
day 3 and the other two by day 4. 
All mice in the 50 pg SEB group 
died by day 5.  None of the mice 
given  BSS  alone  or  the  mutant 
toxins died. 
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Figure 8.  Structural predictions from the primary amino 
acid sequence of SEB. Predictions of hydrophilicity and 
secondary structure are shown for the NHz-terminal 97 
amino acids of SEB using MacVector  3.5. The algorithms 
used for secondary prediction were Chou-Fasman (CF) 
and Robson and Gamier (RG).  The three mutant con- 
taining regions are shown at the top of the figure. 
those given BSS alone. Mice given 50 #g of BK-257 were 
unaffected as well; however, those given 100 #g of BR-257 
showed a slight  weight loss followed by recovery. 
These results confirm that in mice the majority of the tox- 
icity of SEB is dependent on its ability to stimulate T cells, 
suggesting that T cell-derived  lymphokines themselves or 
those produced by other cells activated by T cells are very 
important in the mode of action of this toxin. However, the 
small effect of BR-257  at the higher dose raises the possi- 
bility of a contribution from class II-bearing cells directly 
stimulated by bound SEB without T  cell involvement. 
Discussion 
The results presented here identify the NH2-terminal por- 
tion of SEB as important in both MHC binding and V3 in- 
teraction. Three regions were defined with particular amino 
acids in each pinpointed. Mutations in the first region (residues 
9-23)  affected both MHC binding and T  cell interaction. 
The results suggested that 23N was particularly important. 
When the sequences of the S. aureus enterotoxins are aligned 
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for maximum homology (22), this residue is conserved among 
all of the enterotoxins  and toxic shock toxin as well. The 
mutations in region 2 covered residues 41-53. All drastically 
reduced the ability of the toxin to bind to MHC class II with 
a similar effect on their ability to stimulate T cells. About 
half of the mutations involved 44F. Again, this residue is con- 
served among all the enterotoxins,  indicating that this res- 
idue probably plays a critical role in the binding of all of the 
toxins to MHC. Interestingly, none of the mutations in ei- 
ther region 1 or 2 completely obliterated  toxin binding to 
MHC,  and in both cases the T  cell-stimulating ability of 
the mutants could be recovered by adding a large excess 
of toxin.  Perhaps regions  1 and 2 cooperate in the binding 
of the toxin such that both regions must be mutated to elim- 
inate toxin binding completely. Mutations in the third re- 
gion (60N, 61Y) did not affect  binding of the toxins to MHC, 
but did affect their interaction with two V3s, 7 and 8.1. This 
V3-specific effect suggests that these amino acids are impor- 
tant for interaction with some, but perhaps not other, TCR 
V3s. 
There is at present no solved structure for any of the en- terotoxins;  however, several observations are worth noting 
from an analysis of the primary sequence of SEB in regions 
1-3 (Fig. 8). Region 1 is a hydrophilic to neutral stretch with 
23N predicted to lie within an ol helix.  Region 2 is quite 
hydrophobic and predicted to be within a ~ strand. There- 
fore, the side chains of the amino acids (e.g., 44F) may not 
all point into the aqueous phase. The two amino acids of 
region 3 are predicted to lie at the beginning of an extended 
hydrophilic region on the turn at the end of the B stand con- 
taining region 2, and are, therefore, likely to be on the sur- 
face of the molecule. 
These mutations may affect toxin structure in any of sev- 
eral ways. They may identify amino acids whose side chains 
make critical contact with either MHC or VB. They may 
cause local perturbations in the toxin secondary or tertiary 
structure,  which in turn displace other amino acids critical 
in contacting MHC or V~. Finally, they may cause gross al- 
terations in the toxin structure amounting effectively to the 
denaturation of the protein. This third possibility seems un- 
likely, given the independent effect of many of the mutations 
on MHC vs. VB interaction or on interaction with different 
VI3 elements. Furthermore, these mutant SEBs continued to 
bind to most of a panel of 10 anti-SEB mAbs detecting at 
least four independent epitopes (data not shown). However, 
discriminating  between changes in contact amino acids vs. 
those maintaining localized structural elements will require 
a solution  to the toxin structure. 
Two other studies have suggested that the NH2-terminal 
portion of enterotoxins may be important in T cell stimula- 
tion. Pontzer et al. (47) have blocked SEA MHC binding 
and  T  cell stimulation with  synthetic peptides  matching 
SEA NH2-terminal  sequences, and Spero and Molock (48) 
demonstrated weak  T  cell-stimulating  activity with  an 
NH2-terminal, but not COOH-terminal tryptic fragment of 
SEC1. On the other hand, Bohach et al. (49) found that the 
same C-terminal fragment of SEC1 contained  the T  cell 
stimulating activity of the toxin and Blanco et al. (50) found 
amino acids critical to the functions of toxic shock syndrome 
toxin in the COOH-terminal half of the molecule. At the 
moment, we cannot completely reconcile these latter results 
with our own data. Our results certainly argue strongly that 
the COOH-terminal part of SEB cannot be sufficient for its 
superantigen activity. However, our results do not exclude 
a role for amino acids in the COOH-terminal half of the 
protein, although they indicate that random point mutations 
do not easily reveal these amino  acids. 
Recently, the 3' LTRs of mouse mammary tumor viruses 
have been found to encode a superantigens (vSAG) (51, 52). 
These proteins are of similar molecular weight to the bac- 
terial toxins. Comparison of the sequences of vSAGs with 
different  V3  specificities has  strongly suggested  that  the 
COOH terminus of these proteins determine VB specificity. 
However, this observation is probably not relevant to map- 
ping the VB interaction site on the bacterial toxins, since there 
is no sequence homology  between the two types of superan- 
tigens. Furthermore, these proteins may interact with MHC 
in fundamentally  different  ways, since the toxins bind as soluble 
proteins, while the evidence indicates that vSAGs are type 
II integral membrane proteins with their NH2 terminus cy- 
toplasmic and their COOH terminus extraceUular (Choi et 
al., manuscript in preparation). 
Systemic exposure to any of the S.  aureus enterotoxins  or 
other exotoxins can be associated  with fatal shock in humans, 
mice, and other species. Each of these toxins has ability to 
bind to class II MHC, but each interacts with a different set 
of V~ elements. This observation a priori argues strongly 
that the ability to stimulate T cells is an important and con- 
served feature of the mode of action of these toxins, and that 
it is necessary that stimulation involves a large set of T cells 
regardless of the specificities  of the T cells involved. We have 
suggested that the massive  release of  cytokines accompanying 
this T  cell stimulation is largely responsible for the toxin 
pathology (27), but the ability of toxins to bind to class II 
molecules on macrophages may be sufficient to induce the 
symptoms of these toxins through the direct stimulation of 
macrophage cytokine production without the involvement 
of T  cells. 
The results presented here are consistent with the former 
view in that mutations affecting either VB or MHC binding 
eliminated  the  fatal  toxic  effects  of  SEB  injected  in- 
traperitoneally in mice. SEB and the other enterotoxins, how- 
ever, are most often encountered by ingestion,  which in 
humans usually results in a less serious disease involving a 
short episode of vomiting and diarrhea. At present we do 
not know that these symptoms are also dependent on the 
T cell-stimulating properties of SEB, and it is possible that 
this is a separate function of the toxin mapping elsewhere 
in its structure. If this were the case, our findings would focus 
attention of the COOH-terminal half of the molecule. Un- 
fortunately, we can not test this idea in mice since there is 
at present no rodent model for this disease. 
Lastly,  our  results  indicate  that  the  stretches  of  the 
staphylococcal  toxins that bind MHC and VB are intertwined 
in the primary sequence of the toxins rather than separated 
into two distinct domains. This close association of the VB 
and MHC binding sites of SEB suggests that for successful 
recognition the TCR may be forced into intimate contact 
with both the toxin and MHC component of the complex. 
Perhaps this explains why occasional  individual TCRs bearing 
the appropriate V/3 element nevertheless  fail to recognize toxin 
bound to a particular  aUelic or xenogeneic form of class II 
MHC (16), since in these cases interaction between residues 
in VB or the other receptor variable  elements and polymorphic 
residues of the MHC molecule may interfere with V~toxin 
interactions. 
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